Efficacy and Tolerability of Olmesartan, Telmisartan, and Losartan in Patients of Stage I Hypertension: A Randomized, Open-label Study.

Autor: Kalikar M; Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India., Nivangune KS; Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India., Dakhale GN; Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India., Bajait CS; Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India., Sontakke SD; Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India., Motghare VM; Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India., Budania R; Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India.
Jazyk: angličtina
Zdroj: Journal of pharmacology & pharmacotherapeutics [J Pharmacol Pharmacother] 2017 Jul-Sep; Vol. 8 (3), pp. 106-111.
DOI: 10.4103/jpp.JPP_39_17
Abstrakt: Objectives: To compare the efficacy and tolerability of losartan, telmisartan, and olmesartan as antihypertensive agents and evaluate and compare their effects on lipid profile and blood glucose.
Materials and Methods: This was a randomized, open-label, parallel-group, comparative study conducted in sixty patients of Stage I hypertension. The eligible patients were randomly allocated into three treatment groups: (1) Tablet olmesartan (20 mg), (2) Tablet telmisartan (40 mg), and (3) Tablet losartan (50 mg). Blood pressure (BP) was assessed at an interval of 2 weeks for 3 months. Fasting blood glucose (FBG) and lipid profile were estimated at baseline and then at 12 weeks.
Results: Olmesartan and telmisartan were more efficacious than losartan in reducing diastolic BP (DBP). There was a statistically significant decrease in mean blood glucose level ( P < 0.02) after 12 weeks of treatment in telmisartan group when compared to baseline. Serum total cholesterol, triglycerides, and low-density lipoproteins decreased significantly after 12-week treatment with olmesartan and telmisartan.
Conclusions: The most efficacious drug in reducing BP is Olmesartan whereas telmisartan and losartan show equal efficacy. Telmisartan shows the most favorable effects on FBG and lipid profile.
Competing Interests: There are no conflicts of interest.
Databáze: MEDLINE
Externí odkaz: